Full Papers
Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis
M.G. Silva1, S.M. Oba-Shinjo2, S.K. Marie3, S.K. Shinjo4
- Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Brazil.
- Department of Neurology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Brazil.
- Department of Neurology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Brazil.
- Division of Rheumatology, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Brazil. samuel.shinjo@gmail.com
CER11580
2019 Vol.37, N°4
PI 0656, PF 0662
Full Papers
Free to view
(click on article PDF icon to read the article)
PMID: 30620283 [PubMed]
Received: 02/08/2018
Accepted : 26/10/2018
In Press: 20/12/2018
Published: 27/06/2019
Abstract
OBJECTIVES:
To assess serum interleukin (IL)-17A levels in patients with dermatomyositis (DM) and polymyositis (PM) and correlate them with the demographic, clinical, laboratory and therapeutic data of these diseases.
METHODS:
This was a cross-sectional, single-centre study that included defined DM and PM patients who were age-, gender- and ethnicity-matched to healthy individuals. Serum IL-17A analysis, as well as analysis for other cytokines (IL-6, TNFα and IFNγ), was performed by multiplex immunoassay. The disease status parameters were based on the International Myositis Assessment and Clinical Studies Group (IMACS) set scores.
RESULTS:
Eighty DM, 32 PM patients and 104 healthy individuals were enrolled. Mean age of patients with DM and PM was 46.0 and 47.7, respectively, with a predominance of women and white ethnicity in both groups. Overall, clinical, laboratory, therapeutic, and current disease status were similar among patients with DM and PM. Median serum IL-17A level was higher in patients with PM and DM than the control group (0.73 vs. 0.49 vs. 0.35 pg/mL, respectively; p<0.050) and higher in PM when compared to DM (p<0.001). In DM, serum IL-17A levels were associated with cumulative cutaneous lesions, IMACS parameters, and serum IL-6 and IFNγ levels. In PM, serum IL-17A levels correlated with patients’ current age, IMACS parameters and serum TNFα and IFNγ levels.
CONCLUSIONS:
Serum IL-17A levels are not only increased, but also associated with disease activity in patients with DM and PM. Our data strongly suggest that IL-17A may be a biomarker of disease activity for these systemic autoimmune myopathies.
